Business
Clinical Trials
Clinical Trials.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n Allergy Therapeutics PLC\n11 October 2006\n\n\n\n\n\n\nPOSITIVE OUTCOME FROM POLLINEX(R) QUATTRO RAGWEED DOSE RANGING STUDY AND\nSUCCESSFUL COMPLETION OF PHASE II PROGRAMME\n\n\nAllergy Therapeutics (\"The Company\") plc, the specialist pharmaceutical company\nfocused on allergy vaccination, announces today that it has achieved a positive\noutcome in a dose-ranging study on Pollinex Quattro Ragweed and has now\nsuccessfully completed Phase II with this therapeutic vaccine.\n\n\nPollinex Quattro is an ultra-short course vaccine requiring only four shots in\nthree weeks and incorporates the TLR4 agonist adjuvant MPL(R). Pollinex Quattro\nhas the potential to transform allergy treatment, by providing a proven safe,\neffective and convenient method of vaccination. The Company has three programmes\nof Pollinex Quattro allergy vaccines in clinical development: Grass, Tree and\nRagweed. The Company is planning on commencing Phase III studies in both Ragweed\nand Grass allergies in late 2006 and early 2007. With additional late stage\nstudies also planned in the treatment of Tree allergies, Pollinex Quattro is\nentering the final stages of the largest ever allergy vaccine development\nprogramme and the first conducted on a global basis. The Company expects to\nlaunch the first ever approved allergy vaccine in the United States in 2009.\n\n\nThe dose ranging study, R203, demonstrated that the therapeutic dose of Pollinex\nQuattro Ragweed is clearly immunogenic in a dose related manner. The therapeutic\ndose showed a five fold increase in immune response (IgG) after only four\ninjections, as compared with a three fold increase in the intermediate dose\ngroup and a two fold increase in the low dose group.\n\n\nSince 2005, eleven studies have been conducted with Pollinex Quattro in North\nAmerica involving 700 patients. Further evidence of the safety and efficacy of\nPollinex Quattro is supported in clinical practice via data collected by the\nCompany during named patient use of the vaccine in over 79,000 sufferers in\nEurope.\n\n\nKeith Carter, Chief Executive Officer of Allergy Therapeutics, said: \"Today's\nannouncement is the latest of a series of very positive development milestones\nin the process for achieving global registration and commercialisation of\nPollinex Quattro. The global market for allergy vaccines is substantial and ...